AP1747A - Use of 6-chloro-5-(2-ä4-Äimino-(2-methylsulfanylphenyl)-methylÜpiperazine-1-ylü-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of disorder or condition in a mammal. - Google Patents

Use of 6-chloro-5-(2-ä4-Äimino-(2-methylsulfanylphenyl)-methylÜpiperazine-1-ylü-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of disorder or condition in a mammal.

Info

Publication number
AP1747A
AP1747A AP2005003272A AP2005003272A AP1747A AP 1747 A AP1747 A AP 1747A AP 2005003272 A AP2005003272 A AP 2005003272A AP 2005003272 A AP2005003272 A AP 2005003272A AP 1747 A AP1747 A AP 1747A
Authority
AP
ARIPO
Prior art keywords
äimino
ylü
methylüpiperazine
methylsulfanylphenyl
indol
Prior art date
Application number
AP2005003272A
Other languages
English (en)
Other versions
AP2005003272A0 (en
Inventor
Chandra Aggarwal Prakash
Teresa Annette Smolarek
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26903852&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=AP1747(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of AP2005003272A0 publication Critical patent/AP2005003272A0/xx
Application granted granted Critical
Publication of AP1747A publication Critical patent/AP1747A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Anesthesiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)
AP2005003272A 2000-06-02 2001-05-31 Use of 6-chloro-5-(2-ä4-Äimino-(2-methylsulfanylphenyl)-methylÜpiperazine-1-ylü-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of disorder or condition in a mammal. AP1747A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US20913600P 2000-06-02 2000-06-02
US21217200P 2000-06-16 2000-06-16

Publications (2)

Publication Number Publication Date
AP2005003272A0 AP2005003272A0 (en) 2005-03-31
AP1747A true AP1747A (en) 2007-05-31

Family

ID=26903852

Family Applications (2)

Application Number Title Priority Date Filing Date
AP2005003272A AP1747A (en) 2000-06-02 2001-05-31 Use of 6-chloro-5-(2-ä4-Äimino-(2-methylsulfanylphenyl)-methylÜpiperazine-1-ylü-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of disorder or condition in a mammal.
APAP/P/2001/002180A AP1831A (en) 2000-06-02 2001-05-31 Use of 6-chloro-5-(2-[4-[imino-(2-methylsulfonylphenyl)methyl]-piperazine-1-yl]-ethyl)-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of phobia.

Family Applications After (1)

Application Number Title Priority Date Filing Date
APAP/P/2001/002180A AP1831A (en) 2000-06-02 2001-05-31 Use of 6-chloro-5-(2-[4-[imino-(2-methylsulfonylphenyl)methyl]-piperazine-1-yl]-ethyl)-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of phobia.

Country Status (44)

Country Link
US (1) US20060287336A1 (is)
EP (3) EP1286672B1 (is)
JP (2) JP2003534381A (is)
KR (1) KR20030007824A (is)
CN (1) CN1431901A (is)
AP (2) AP1747A (is)
AR (1) AR028937A1 (is)
AT (3) ATE345818T1 (is)
AU (1) AU2001258690A1 (is)
BG (1) BG107267A (is)
BR (1) BR0111271A (is)
CA (1) CA2410618A1 (is)
CY (1) CY1105992T1 (is)
CZ (1) CZ20023860A3 (is)
DE (3) DE60133596D1 (is)
DK (1) DK1468686T3 (is)
DO (1) DOP2001000181A (is)
EA (1) EA007068B1 (is)
EC (1) ECSP024369A (is)
EE (1) EE200200670A (is)
ES (1) ES2277170T3 (is)
GE (1) GEP20053512B (is)
HN (1) HN2001000119A (is)
HR (1) HRP20020953A2 (is)
HU (1) HUP0301747A2 (is)
IL (2) IL152782A0 (is)
IS (1) IS6619A (is)
MA (1) MA26908A1 (is)
MX (1) MXPA02011862A (is)
NO (1) NO325077B1 (is)
NZ (1) NZ551012A (is)
OA (1) OA12267A (is)
PA (1) PA8518301A1 (is)
PE (1) PE20011329A1 (is)
PL (1) PL365576A1 (is)
PT (2) PT1698338E (is)
SI (1) SI1468686T1 (is)
SK (1) SK16622002A3 (is)
SV (1) SV2002000473A (is)
UA (1) UA79425C2 (is)
UY (1) UY26742A1 (is)
WO (1) WO2001091756A2 (is)
YU (1) YU90702A (is)
ZA (1) ZA200209665B (is)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2003296991A1 (en) 2002-12-13 2004-07-09 Regents Of The University Of Minnesota Scleral depressor
WO2005040160A2 (en) 2003-10-24 2005-05-06 Teva Pharmaceutical Industries Ltd. Processes for preparation of ziprasidone
ES2250001B1 (es) * 2004-09-29 2007-06-01 Medichem, S.A. Proceso para la purificacion de ziprasidona.
JP2012174228A (ja) * 2011-02-24 2012-09-10 Kyocera Corp プログラム保護装置および通信装置
US20140206667A1 (en) 2012-11-14 2014-07-24 Michela Gallagher Methods and compositions for treating schizophrenia
US9981041B2 (en) * 2016-08-23 2018-05-29 Ira Jason Salzman Ophthalmic lubricating spray

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0985414A2 (en) * 1998-05-26 2000-03-15 Pfizer Products Inc. Method of treating glaucoma and ischemic retinopathy
WO2000059489A2 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW491847B (en) * 1996-05-07 2002-06-21 Pfizer Mesylate dihydrate salts of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)-ethyl)-6-chloro-1,3-dihydro-2h-indol-2-one
HU229057B1 (en) * 1996-05-07 2013-07-29 Pfizer Mesylate trihydrate salt of 5-(2-(4-(1,2-benzisothiazol-3-yl)-1-piperazinyl)ethyl)-6-chloro-1,3-dihydro-2(1h)-indol-2-one (-ziprasidone), its preparation and its use as dopamine d2 antagonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0985414A2 (en) * 1998-05-26 2000-03-15 Pfizer Products Inc. Method of treating glaucoma and ischemic retinopathy
WO2000059489A2 (en) * 1999-04-06 2000-10-12 Sepracor Inc. Methods and compositions for the treatment of psychotic and related disorders using ziprasidone metabolites

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
PRAKASH C ET AL: DRUG METABOLISM AND DISPOSITION, vol. 25, no. 7, July 1997, pages 863-872 *

Also Published As

Publication number Publication date
AP1831A (en) 2008-02-26
DOP2001000181A (es) 2002-04-15
AR028937A1 (es) 2003-05-28
NO325077B1 (no) 2008-01-28
UY26742A1 (es) 2001-12-28
EP1468686B1 (en) 2006-11-22
ATE343387T1 (de) 2006-11-15
CY1105992T1 (el) 2011-04-06
EP1698338B1 (en) 2008-04-09
SV2002000473A (es) 2002-10-24
CA2410618A1 (en) 2001-12-06
IL152782A0 (en) 2003-06-24
WO2001091756A2 (en) 2001-12-06
ES2277170T3 (es) 2007-07-01
SK16622002A3 (sk) 2004-07-07
GEP20053512B (en) 2005-05-10
DE60124093D1 (de) 2006-12-07
NO20025760L (no) 2003-01-15
AU2001258690A1 (en) 2001-12-11
PL365576A1 (en) 2005-01-10
KR20030007824A (ko) 2003-01-23
PT1468686E (pt) 2007-01-31
AP2005003272A0 (en) 2005-03-31
HRP20020953A2 (en) 2005-02-28
IL152782A (en) 2007-10-31
EP1468686A3 (en) 2004-12-01
ECSP024369A (es) 2003-02-06
DK1468686T3 (da) 2007-03-12
BR0111271A (pt) 2003-06-10
HN2001000119A (es) 2001-09-11
EE200200670A (et) 2004-08-16
MXPA02011862A (es) 2003-04-10
EA007068B1 (ru) 2006-06-30
PT1698338E (pt) 2008-06-03
JP2008056700A (ja) 2008-03-13
UA79425C2 (en) 2007-06-25
DE60124791D1 (de) 2007-01-04
BG107267A (bg) 2003-06-30
EP1698338A2 (en) 2006-09-06
IS6619A (is) 2002-11-14
EA200201168A1 (ru) 2003-06-26
CZ20023860A3 (cs) 2004-01-14
EP1468686A2 (en) 2004-10-20
ATE345818T1 (de) 2006-12-15
OA12267A (en) 2004-01-20
EP1698338A3 (en) 2006-09-20
MA26908A1 (fr) 2004-12-20
PA8518301A1 (es) 2002-09-17
NO20025760D0 (no) 2002-11-29
YU90702A (sh) 2005-11-28
JP2003534381A (ja) 2003-11-18
HUP0301747A2 (hu) 2003-09-29
CN1431901A (zh) 2003-07-23
ATE391507T1 (de) 2008-04-15
SI1468686T1 (sl) 2007-04-30
NZ551012A (en) 2008-04-30
US20060287336A1 (en) 2006-12-21
ZA200209665B (en) 2003-11-28
PE20011329A1 (es) 2002-01-15
WO2001091756A3 (en) 2002-09-26
EP1286672B1 (en) 2006-10-25
DE60124791T2 (de) 2007-09-13
DE60133596D1 (de) 2008-05-21
EP1286672A2 (en) 2003-03-05

Similar Documents

Publication Publication Date Title
MXPA03005731A (es) Articulo absorbente que tiene tratamientos medicinales liberables.
PL362690A1 (en) Combinations of drugs (e.g., chlorpromazine and pentamidine) for the treatment of neoplastic disorders
AU2001292297A1 (en) Mouthpiece for orthodontic treatment and device for orthodontic treatment using the mouthpiece
PL388076A1 (pl) Doustna postać dawki o przedłużonym uwalnianiu oksykodonu i jej zastosowanie
IL153708A0 (en) Benzimidazole derivatives, preparation and therapeutic use thereof
PT1827396T (pt) Medicamento oral de libertação modificada de pelo menos um princípio ativo sob forma multimicrocapsular
IL196301A0 (en) Medicament for the treatment of hapatitis c
ZA200300316B (en) Rapidly decomposing administrable form for releasing active ingredient in the oral cavity or in body cavities.
ZA200203156B (en) Use of dipyridamole or mopidamol in the manufacture of a medicament for the treatment and prevention of fibrindependent microcirculation disorders.
ZA200204493B (en) Pharmaceutical combinations and their use in treating gastrointestinal disorders.
HUP0301333A3 (en) Pharmaceutical superdisintegrant, process for its preparation and its use
HRP20010655B1 (en) Pyridopyranoazepine derivatives, preparation and therapeutic use
ZA200000171B (en) Analgesic with controlled active substance release.
GB2368525B (en) Hyaluronan as a cytotoxic agent, drug pre-sensitizer and chemo-sensitizer in the treatment of disease
AU2001264044A1 (en) 1,4-diazabicyclo(3.2.2)nonabenzoxazole, -benzothiazole and benzimidazole derivatives, preparation and therapeutic use thereof
MXPA02012249A (es) Peptidos, composiciones y metodos para el tratamiento de burkholderia cepacia.
ZA200400313B (en) Use of BIBN4096 in combination with other antimigraine drugs for the treatment of migraine.
AU2001268710A1 (en) Pharmaceuticals for the imaging of angiogenic disorders for use in combination therapy
AP1747A (en) Use of 6-chloro-5-(2-ä4-Äimino-(2-methylsulfanylphenyl)-methylÜpiperazine-1-ylü-1,3-dihydro-indol-2-one for the preparation of a medicament for the treatment of disorder or condition in a mammal.
EE05211B1 (et) Saredutandi ja selle farmatseutiliselt vastuv?etavate soolade kasutamine meeleoluh„irete, kohanemish„irete v?i segatpi „rev-depressiivsete h„irete raviks v?i v„ltimiseks kasulike ravimite valmistamiseks
ZA200205464B (en) Device for preventing or relieving pain in the lower back.
MXPA03003032A (es) Terapia de combinacion para el tratamiento de una enfermedad sensible a los estrogenos.
HUP0201810A3 (en) Sootepenseone and its derivatives, their preparation and use as medicament
AU2002215187A1 (en) S-adenosylmethionine and derivatives thereof for the treatment and prevention ofalzheimer's disease
MXPA03005395A (es) Derivados de dihidroindol y tetrahidroquinolina.